Apply to trial NCT07133750

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

PM8002 (BNT327) is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II trial to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in first line MSS or MSI-L/pMMR metastatic colorectal cancer.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening